Evidence map›Paper›PMID 35236371›Full record

SynthesisOrphanet journal of rare diseases2022

Rosai-Dorfman-Destombes disease of the nervous system: a systematic literature review.

Ruham Alshiekh Nasany, Anne S Reiner, Jasmine H Francis, Oussama Abla, Katherine S Panageas, Eli L Diamond

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Nasopharyngeal Representation of Rosai-Dorfman Disease; a Case Report.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Neurological Manifestations of Histiocytic Disorders.Current neurology and neuroscience reports · 2023
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ruham Alshiekh NasanyDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 160 East 53rd Street, 2nd Floor, New York, NY, 10022, USA.
Anne S ReinerDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jasmine H FrancisOphthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Oussama AblaDivision of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Katherine S PanageasDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eli L DiamondDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 160 East 53rd Street, 2nd Floor, New York, NY, 10022, USA. diamone1@mskcc.org.ORCID 0000-0001-5456-5961
Memorial Sloan Kettering Cancer Center · USHospital for Sick Children · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Molecular Pathogenesis and Therapy of Systemic Histiocytic NeoplasmsR37CA259260 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eli Lous Diamond · 2021 to 2026
$3.3M
NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA259260NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundRosai-Dorfman-Destombes disease (RDD) is a rare histiocytic disorder with heterogeneous clinical manifestations and rare neurologic involvement. The existing clinical literature about neurologic RDD has yet to be critically examined.

methodsWe performed a four-database English-language systematic literature search for cases of RDD neurohistiocytosis, excluding secondary literature. Individual patient data for neurologic symptoms, disease sites, treatments, and responses were captured. Responses to first-line and second-line surgical interventions, post-surgical radiotherapy, and systemic therapies were analyzed.

resultsAmong 4769 articles yielded by literature search, 154 articles were fully reviewed, containing data on 224 patients with neurologic RDD. 128 (83.1%) articles were single case reports. 149 (66.5%) patients were male, 74 (33.5%) female, with a median age of 37.6 years (range 2-79). Presenting neurologic symptoms included headache (45.1%), focal neurological deficits (32.6%), visual symptoms (32.1%), and seizures (24.6%). RDD involvement was multifocal in 32 (14.3%) cases. First-line treatment involved resection in 200 (89.6%) patients, with subsequent progression in 52 (26%), including 41 (78.8%) with unifocal disease. No difference was observed in progression-free survival comparing post-operative radiotherapy to no radiotherapy following partial resection. Chemotherapy given alone as first-line treatment led to complete or partial response in 3/7(43%) patients. Second-line treatments led to complete or partial response in 18/37(37.5%) patients. Mutational data were reported on 10 patients (4.46%).

conclusionsThis review highlights the limited published data about neurologic RDD, which presents with varied symptomatology and outcome. Further study is needed about its mutational landscape, and more effective therapies are needed for recurrent and refractory disease.

Indexed as

Histiocytosis, SinusAdolescentAdultAgedChildChild, PreschoolFemaleHumansMaleMiddle AgedNervous SystemYoung AdultHistiocytosisMAPK pathwayRosai–Dorfman diseaseSystematic review

Identifiers

PMID35236371
PMCPMC8889645
OpenAlexW4214870022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.